Friedreich's Ataxia Natural History Study
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study follows people with Friedreich's ataxia (FA) over time to learn more about the disease. It helps researchers understand how FA affects people of all ages and may lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of Friedreich's ataxia (FA).
- You or your legal representative must be able to give informed consent.
- You cannot have other medical conditions that would interfere with the study.
- You must be willing and able to follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how heart disease progresses in people with Friedreich's ataxia, a genetic condition that affects coordination and heart health. By taking part, you help researchers better understand the condition, which may guide future treatments.
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
This study looks at the long-term safety of omaveloxolone (BIIB141) for people with Friedreich's ataxia. You can join if you are just starting this medicine or have been taking it for less than a year.
This trial tests an investigational drug called DT-216P2 in people with Friedreich's ataxia. It aims to find the right dose and see how safe and tolerable it is.
This study uses patient-reported questionnaires and health/economics/psychosocial questions for people with Friedreich ataxia. It aims to better understand how the condition affects daily life and what outcomes matter most, which can help future care and research.
This study tests a new medicine called DT-216P2 in healthy people to find a safe dose. It is a first step in developing a treatment for Friedreich ataxia, a genetic condition that affects movement and balance.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.